XML 90 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Arrangements - Pfizer Enzyme Supply Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2023
Aug. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Liability, revenue recognized     $ 1,500        
Sales revenue, goods     138,590 $ 104,754 $ 69,056    
Contract liabilities: deferred revenue $ 30,609 $ 30,609 30,609 6,335      
Pfizer | Enzyme Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Contract with customer, liability, retainer fee             $ 25,900
Liability, revenue recognized   36,800 75,400 34,500      
Sales revenue, goods 19,800   0 $ 1,700      
Contract liabilities: deferred revenue $ 24,400 $ 24,400 $ 24,400        
Pfizer | Enzyme Product | Subsequent Event              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Accounts and other receivables, net, current           $ 16,900  
Pfizer | Enzyme Product | Revenue from Contract with Customer Benchmark | Customer Concentration Risk              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Concentration risk, percentage     54.00% 33.00%